World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
76
Citations
42592
World Ranking
18599
National Ranking
9264

Overview

Robin Kate Kelley is affiliated with the University of California, San Francisco in the United States and has a research focus primarily in the field of Medicine, with significant contributions to Oncology. Their work spans several subfields including Oncology, Hepatology, Surgery, Pulmonary and Respiratory Medicine, and Epidemiology.

The scientist's main research topics cover a wide range of cancer-related studies and liver diseases. These include:

  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Pancreatic and Hepatic Oncology Research
  • Cancer Immunotherapy and Biomarkers
  • Liver Disease Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Fibroblast Growth Factor Research

Robin Kate Kelley has published research extensively, with a selection of notable recent papers listed below:

  • "Hepatocellular carcinoma," 2021, Nature Reviews Disease Primers
  • "BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update," 2021, Journal of Hepatology
  • "Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma," 2022, NEJM Evidence
  • "Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology," 2021, Journal of the National Comprehensive Cancer Network
  • "Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study," 2020, The Lancet Oncology

The scientist frequently publishes in the following venues, reflecting a focus on oncology and hepatology:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal of Hepatology
  • Cancer Research
  • Clinical Cancer Research

Collaboration is a notable aspect of Robin Kate Kelley's work, with frequent coauthors including:

  • Ghassan K. Abou-Alfa
  • Lipika Goyal
  • Bruno Sangro
  • Lorenza Rimassa
  • Junji Furuse

Best Publications

  • Oncogenic Signaling Pathways in The Cancer Genome Atlas

    Francisco Sanchez-Vega;Marco Mina;Joshua Armenia;Walid K. Chatila

  • Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

    Katherine A. Hoadley;Christina Yau;Christina Yau;Toshinori Hinoue;Denise M. Wolf

  • Comprehensive Characterization of Cancer Driver Genes and Mutations.

    Matthew H Bailey;Collin Tokheim;Eduard Porta-Pardo;Sohini Sengupta

  • Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma

    Adrian Ally;Miruna Balasundaram;Rebecca Carlsen;Eric Chuah

  • Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

    Andrew X Zhu;Richard S Finn;Julien Edeline;Stephane Cattan

  • Hepatocellular carcinoma.

    Josep M Llovet;Robin Kate Kelley;Augusto Villanueva;Amit G Singal

  • Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

    Ghassan K. Abou-Alfa;Tim Meyer;Ann Lii Cheng;Anthony B. El-Khoueiry

  • Cholangiocarcinoma — evolving concepts and therapeutic strategies

    Sumera Rizvi;Shahid A. Khan;Christopher L. Hallemeier;Robin K. Kelley

  • Genomic and Functional Approaches to Understanding Cancer Aneuploidy

    Alison M. Taylor;Alison M. Taylor;Juliann Shih;Gavin Ha;Gavin Ha;Galen F. Gao

  • Pathogenic Germline Variants in 10,389 Adult Cancers

    Kuan-Lin Huang;R Jay Mashl;Yige Wu;Deborah I Ritter

  • Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

    Ghassan K. Abou-Alfa;Ghassan K. Abou-Alfa;Teresa Macarulla;Milind M. Javle;Robin K. Kelley

  • Hepatobiliary cancers, Version 2.2021

    Al B. Benson;Michael I. D'Angelica;Daniel E. Abbott;Daniel A. Anaya

  • Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

    Milind Javle;Maeve Lowery;Rachna T. Shroff;Karl Heinz Weiss

  • Erratum: Comprehensive Characterization of Cancer Driver Genes and Mutations (ARTICLE (2018) 173(2) (371–385), (S009286741830237X), (10.1016/j.cell.2018.02.060))

    Matthew H. Bailey;Collin Tokheim;Eduard Porta-Pardo;Sohini Sengupta

  • Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

    John D. Gordan;Erin B. Kennedy;Ghassan K. Abou-Alfa;Muhammad Shaalan Beg

  • Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas

    Franz X. Schaub;Varsha Dhankani;Ashton C. Berger;Mihir Trivedi

  • Efficacy and Safety of Pembrolizumab for the Treatment of Advanced Biliary Cancer: Results From the KEYNOTE-158 and KEYNOTE-028 Studies

    Sarina A. Piha-Paul;Do Youn Oh;Makoto Ueno;David Malka

  • Hepatobiliary Cancers, Version 1.2017: Featured Updates to the NCCN Guidelines

    Al B. Benson;Michael I. D'Angelica;Daniel E. Abbott;Thomas A. Abrams

  • Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

    Robin Kate Kelley;Bruno Sangro;William Harris;Masafumi Ikeda

  • Systemic therapies for intrahepatic cholangiocarcinoma.

    Robin Kate Kelley;John Bridgewater;Gregory J. Gores;Andrew X. Zhu

Frequent Co-Authors

Ghassan K. Abou-Alfa
Ghassan K. Abou-Alfa Memorial Sloan Kettering Cancer Center
Alan P. Venook
Alan P. Venook University of California, San Francisco
Milind Javle
Milind Javle The University of Texas MD Anderson Cancer Center
Ann-Lii Cheng
Ann-Lii Cheng National Taiwan University
Andrew X. Zhu
Andrew X. Zhu Harvard University
Jee Woo Park
Jee Woo Park Seoul National University
Tim Meyer
Tim Meyer University College London
Juan W. Valle
Juan W. Valle University of Manchester
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA doesn't always mean becoming a physician. There are diverse online degree options and career pathways to consider, each with unique entry requirements and career outcomes.

For those interested in administrative or non-clinical healthcare roles, medical coding and billing classes online with financial aid can quickly open doors to jobs in hospitals, insurance companies, or private practices. Many of these programs offer financial assistance, making them accessible for students from various backgrounds.

Aspiring nurses who want to avoid lengthy entrance exams can explore nursing schools that don't require teas. These programs help fast-track your entrance into the nursing field without the added stress of standardized tests.

If leadership roles in healthcare appeal to you, an online healthcare administration degree accelerates your path toward managing clinics, hospitals, or specialized health departments.

Registered Nurses wishing to advance can consider rn to np bridge programs, which are efficient pathways to become nurse practitioners and take on more advanced responsibilities.

Best Scientists Citing Robin Kate Kelley

Trending Scientists